A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

• Status: Recruiting
• Trial end date: 2023-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alumis Inc

Criteria

Inclusion Criteria:

• Total body weight >40 kg (88 lb)

• Men and woman age 18-75

• Men and Women must use highly effective methods of contraception for the entirety of the study

Exclusion Criteria:

• History of malignancy within the last 5 years

• Positive for HIV, Hepatitis B or C

• History of tuberculosis

• Diagnosis of non-plaque psoriasis

• Patients with QTcF >450 msec (males) or >470 msec (females) at screening

• Live vaccines